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AbstrACt
background Most of the reduction in malaria prevalence 
seen in Africa since 2000 has been attributed to vector 
control interventions. Yet increases in the distribution and 
intensity of insecticide resistance and higher costs of 
newer insecticides pose a challenge to sustaining these 
gains. Thus, endemic countries face challenging decisions 
regarding the choice of vector control interventions.
Methods A cluster randomised trial is being carried out in 
Mopeia District in the Zambezia Province of Mozambique, 
where malaria prevalence in children under 5 is high (68% 
in 2015), despite continuous and campaign distribution 
of long-lasting insecticide-treated nets (LLINs). Study 
arm 1 will continue to use the standard, LLIN-based 
National Malaria Control Programme vector control 
strategy (LLINs only), while study arm 2 will receive 
indoor residual spraying (IRS) once a year for 2 years with 
a microencapsulated formulation of pirimiphos-methyl 
(Actellic 300 CS), in addition to the standard LLIN strategy 
(LLINs+IRS). Prior to the 2016 IRS implementation (the 
first of two IRS campaigns in this study), 146 clusters were 
defined and stratified per number of households. Clusters 
were then randomised 1:1 into the two study arms. 
The public health impact and cost-effectiveness of IRS 
intervention will be evaluated over 2 years using multiple 
methods: (1) monthly active malaria case detection in 
a cohort of 1548 total children aged 6–59 months; (2) 
enhanced passive surveillance at health facilities and with 
community health workers; (3) annual cross-sectional 
surveys; and (4) entomological surveillance. Prospective 
microcosting of the intervention and provider and societal 
costs will be conducted. Insecticide resistance status 
pattern and changes in local Anopheline populations will 
be included as important supportive outcomes.
Discussion By evaluating the public health impact and 
cost-effectiveness of IRS with a non-pyrethroid insecticide 
in a high-transmission setting with high LLIN ownership, it 
is expected that this study will provide programmatic and 
policy-relevant data to guide national and global vector 
control strategies.
trial registration number NCT02910934.
bACkgrounD
Around 80% (73%–88%) of the total reduc-
tion in malaria prevalence seen in Africa 
since 2000 is attributed to vector control 
interventions.1 However, increases in the 
distribution and intensity of insecticide resist-
ance, particularly resistance to pyrethroids, 
in key vector populations pose a formidable 
Key questions
What is already known about this topic?
 ► There is conflicting evidence on the public health 
impact and cost-effectiveness of combining long-
lasting insecticide-treated nets (LLINs) and indoor 
residual spraying (IRS) for malaria control, and little 
information on the impact on insecticide resistance, 
particularly with novel IRS active ingredients.
What are the new findings?
 ► This trial randomly assigned 43 of 86 clusters to 
receive IRS with Actellic 300 CS in an area with 
high and ongoing LLIN coverage.
 ► Epidemiological impact is assessed through 
active case detection in a cohort of children under 
5 residing in the core area of each cluster and 
through enhanced passive surveillance at each 
health facility in the district.
 ► Economic outcome is marginal cost per a malaria 
case averted through IRS with Actellic on top of 
LLINs in a highly endemic area, as compared with 
LLINs alone.
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challenge to sustaining these hard-won gains.2 3 In this 
context, malaria endemic countries face challenging 
decisions regarding the choice and financing of vector 
control interventions. Country-level decision-makers and 
development partners increasingly look for evidence of 
public health impact and cost-effectiveness of different 
interventions to guide investments.
The WHO recommends that endemic countries 
protect all those at risk of malaria with long-lasting 
insecticide-treated nets (LLINs) or, where appropriate, 
indoor residual spraying (IRS).4 The WHO guidance on 
combining IRS and LLINs states that deploying IRS with 
a non-pyrethroid insecticide in an area with known insec-
ticide resistance should be done only as part of an insec-
ticide resistance management strategy.4 This guidance is 
largely based on data available in March 2014 from cluster 
randomised trials5–8 (see table 1 for all cluster randomised 
trials available to date). These studies, conducted in 
different transmission settings, gave inconsistent evidence 
and did not directly assess the cost or cost-effectiveness of 
the interventions. These findings highlight the question of 
whether or not the impact of IRS in addition to LLINS is 
related to transmission intensity.
Studies with alternative designs suggest but fail to 
clearly demonstrate an incremental benefit in the 
combined use of IRS and LLINs. Hamel et al9 conducted 
a non-randomised prospective trial in a high-transmis-
sion area in Kenya using pyrethroids for IRS. This study 
found a marked decrease in malaria incidence in the 
IRS and LLIN arms. Experimental hut trials have also 
given inconsistent results: in Tanzania two studies using 
different net brands and IRS products found little benefit 
of adding IRS once good LLIN coverage was achieved.10 11 
In Benin, however, Ngufor et al,12 using a similar design, 
showed that IRS with a non-pyrethroid provided addi-
tional levels of transmission control and personal protec-
tion against pyrethroid-resistant mosquitoes. A trial is 
currently ongoing in Ethiopia assessing IRS with carba-
mate in addition to LLINs in an area of seasonal transmis-
sion and relatively low prevalence.13
Additionally, a meta-analysis including data from 
17 countries found the IRS–LLINs combination bene-
ficial in terms of reducing parasitaemia in areas of 
medium or high transmission across sub-Saharan 
Africa.14
This study in Mozambique will provide detailed infor-
mation on the impact (infection burden and insecti-
cide resistance) and cost-effectiveness of adding IRS 
with an extended release formulation of the organo-
phosphate insecticide pirimiphos-methyl (Actellic 300 
CS, Syngenta AG, Basel, Switzerland) in a high-trans-
mission area with high LLIN access before and after an 
LLIN campaign. This information will be disseminated 
to the Programa Nacional de Controlo da Malaria 
(NMCP) as well as to local and international stake-
holders and decision makers to inform policy recom-
mendations and choices regarding the combination of 
vector control strategies.T
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Primary research question
In an area with high malaria endemicity and high LLIN 
access, what is the incremental benefit of IRS on malaria 
incidence and at what level of cost-effectiveness?
MetHoDs
study setting
Mopeia is a district in Zambezia, one of the most impover-
ished provinces in Mozambique (figure 1). The projected 
population for 2016 was 162 188 individuals, with 31 927 
(19.7%) under 5 years of age.15
The malaria burden is high in Zambezia, with a para-
site prevalence of 68% in children under 5 in 2015.16 
The parasite prevalence in children 1–15 years of age 
in Mopeia was 47.8% (38.7%–57.1%) in 2006–2008.17 
Mopeia received 175 297 LLINs through a mass campaign 
in 2013 and IRS in the entire district with pyrethroids in 
2014.18 Pregnant women in Mopeia receive free LLINs 
at their first antenatal care appointment, as per national 
policy. All residents are targeted to receive new LLINs 
in mid-2017 as part of Mozambique’s national LLIN 
universal coverage campaign. Additional malaria control 
activities in the district include access to intermittent 
prevention of malaria in pregnancy, efforts to expand 
appropriate case management and behaviour change 
communication.19
The primary malaria vector species in Mopeia District 
are Anopheles gambiae s.s. and A. funestus s.s., although A. 
arabiensis is present as well. Data from January 2015 in 
the neighbouring districts of Mocuba and Morrumbala 
show pyrethroid resistance (52% and 34% mortality 
24 hours after deltamethrin WHO tube test, and 40% and 
33% mortality after lambda-cyhalothrin, respectively) in 
the local A. gambiae s.l. population.20
study overview
The study is a cluster randomised trial in which all of 
Mopeia’s villages will continue to receive LLINs through 
mass campaigns and routine distribution, and half of the 
villages will be randomised to receive additional IRS with 
Actellic 300 CS.
Cluster assignment and buffering
Households and population including number of chil-
dren under 5 years of age were enumerated in June–
July 2016. This information was used to stratify their 
villages in three groups by population size. Interven-
tion allocation was conducted during a ‘randomization 
ceremony’ in which village representative blindly drew 
spray/no-spray lots from three boxes containing the strat-
ified village names.
A ‘fried egg’ design was chosen for the clusters.21 To 
avoid contamination between clusters with discordant 
Figure 1 Administrative map of Mopeia.
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spray status, a buffer zone of at least 1 km was defined 
around each core area. This was based on typical African 
vector flying and recapture ranges22 23 and previous similar 
trials.5–7 This resulted in at least 2 km separating children 
in discordant spray areas. Villages assigned to the same 
intervention status were classified as single village clusters 
or grouped into larger clusters when required by size. Many 
households were located within 1 km of the village limit 
but more than 2 km away from any other village. Excluding 
these households due to location would result in great loss 
of recruitment opportunities, so we constructed Delaunay 
triangles and subsequently create Voronoi polygons from 
all households’ location. Voronoi tessellation was used to 
‘expand’ each village’s boundary so that it encompasses 
those points in which the villagers live and any point which 
is closer to that village than any other. This process classified 
every point of Mopeia as belonging to the village closest to it 
(figure 2). Buffers were then defined from these expanded 
borders. Buffering between clusters with the same interven-
tion status was deemed unnecessary and could have limited 
the number of eligible participants. In order to reduce 
contamination, an internal buffer zone of at least 1 km 
was defined around each cluster’s core area, and cohort 
members will be selected only from core areas. Each house-
hold was added and colour-coded according to location 
regarding spray and buffer status (figure 3).
Intervention
The villages selected to receive the IRS intervention in 
2016 will receive IRS with Actellic 300 CS once a year for 
2 years according to President’s Malaria Initiative (PMI) 
Africa Indoor Residual Spraying (PMI/AIRS) standard 
operating procedures,24 in addition to standard LLIN 
distribution at both Antenatal Clinics (ANC) and through 
Figure 2 Defining cluster limits and buffers. Voronoi 
tessellation for cluster definition (panel A). Panel B shows 
the Voronoi surface with internal buffers. Panel C shows the 
location of every village, as well as the core and buffer areas.
Figure 3 Merging clusters with same status and buffering 
between clusters. Panel A shows the spray and no-spray 
regions. Panel B shows the 1-km of internal buffer added 
to each spray status zone. In panel C, each household was 
added and colour-coded according to location regarding 
spray and buffer status.
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a 2017 mass distribution campaign. Villages selected to 
not receive the IRS intervention will maintain standard 
of care with LLINs, but will not receive IRS.
In October–November 2017 (prior to study year 2), IRS 
will be repeated in the same villages using the same insec-
ticide product. Additionally, in April–July 2017 the whole 
district was targeted to receive LLINs from the NMCP. 
Information about implementation of interventions will 
be obtained with questionnaires during the monthly 
active cohort visits and during the cross-sectional surveys, 
including questions about wall replastering/painting 
and net usage. Information on quality and duration of 
IRS effect will be obtained through cone bioassays.
The standard of malaria care at community and health 
centre will remain unchanged throughout the study area, 
and stock levels of malaria commodities will be ensured 
by study partners.
study outcomes
Primary outcomes
1. malaria cases averted in children 6–59 months of age 
at the community level by adding IRS (community 
incidence); the study is powered based on this 
outcome
2. cost per malaria case averted in children 6–59 months 
of age at the community level by adding IRS
3. malaria case averted in children 6–59 months of age 
at the health facility level by adding IRS (health facil-
ity incidence)
4. cost per malaria case averted in children 6–59 months 
of age at the health facility level by adding IRS.
Secondary outcomes
1. vector densities, human biting rates, sporozoite rates, 
indoor and outdoor feeding behaviours, prevalence 
and intensity of resistance to pyrethroids, and 
estimates of entomological inoculation rates (EIR) 
as measured or estimated through entomological 
surveillance
2. changes in community-based parasite prevalence
3. incremental impact of combining IRS with LLINs, in-
cluding assessment of the impact of new nets in year 2
4. correlation between incidence at community and 
health facility levels
5. correlation between incidence (community and 
health facility) and prevalence
6. changes in malaria prevention methods including net 
use and in health-seeking behaviour.
Measurement of epidemiological impact
To determine the malaria incidence based on active 
case detection, a cohort of 1548, 774 children per arm, 
will be followed by monthly household visits. The target 
is to recruit 18 children from each cluster who are 
6–59 months of age at time of enumeration (43 clusters per 
arm). During each household visit, a short questionnaire 
will be administered to the caretaker and a rapid diagnostic 
test (RDT) will be performed on the cohort child. If the 
child has a positive RDT, he or she will receive treatment 
according to the national guidelines; hence, any child who 
is RDT-positive at baseline will be cleared of parasitaemia 
for follow-up. Every time a child is treated, 10 days will be 
subtracted from his or her at-risk time given the half-life of 
artemether/lumefantrine.25
To estimate incidence rates via passive surveillance at 
the health facility level, a facility-based team will ensure 
the collection of the household location and RDT test 
result for each febrile patient who presents to a health 
facility. Enhanced passive surveillance will also include 
abstraction of RDT test results and treatment informa-
tion from community health workers.
Cross-sectional studies will be carried out in April to 
May, at the peak of transmission season in 2017 and 
2018, to estimate malaria infection prevalence and 
obtain additional costing and healthcare expenditure 
data. Figure 4 shows the Standard Protocol Items: 
Recommendations for Interventional Trials diagram for 
this study protocol.
Measurement of costing outcomes
Costing data will be prospectively collected using data 
collection tools to determine the cost of IRS and of a case 
of malaria from the societal perspective.
IRS implementation costs will be recorded following an 
ingredient approach or microcosting26: each quantity of 
resource used for the programme will be multiplied by 
its corresponding unit cost or price. Expenditures will be 
inflation-adjusted and converted to US dollars, according 
to the official exchange rate.27
Implementation costs will be classified as financial 
resources needed to carry out IRS implementation,28 and 
economic opportunity costs, which include resources used 
in IRS implementation that do not necessarily involve a 
payment for the project but represent an opportunity cost 
for the society (such as car used in the IRS implementation 
that was not purchased and so on).
Health system costs will be obtained at the health 
facilities using a mixed approach: bottom-up for most 
of the resources used during the hospital visit or admis-
sion (tests and treatments, including the time spent by 
the health worker, lab and pharmacy technician) and 
top-down for overhead costs, in which annual operating 
costs of the health services will be allocated according to 
the proportion of the total number of services provided 
due to malaria in relation to all services. These IRS imple-
mentation and health service costs will be used to deter-
mine the cost from the payer’s perspective.
The societal perspective will include the aforemen-
tioned costs along with those incurred by households and 
individuals. Household direct costs will consist of medical 
and non-medical care, transportation, and others (food, 
telephone and others). Household indirect costs will 
consist of the monetisation of caregiver’s time lost 
(according to Mozambican minimum wage reports29 30). 
These costs will be collected through the cross-sectional 
and active case detection questionnaires.
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Measurement of entomological outcomes
Entomological data, including resistance status and 
its changes, vector densities, sporozoite rates, and 
indoor/outdoor biting ratios will be collected by the 
PMI/AIRS project from both sprayed and non-sprayed 
areas using light traps and human landing catches in a 
subset of 10 villages, five from clusters that receive IRS 
and five from clusters that do not.
In each village assigned for entomological sampling, 
eight households will be randomly selected from the core 
zone for mosquito collection. Monitoring will take place 
on three consecutive nights every month (240 collec-
tions per month) throughout the duration of the study. 
Mosquito collection will be done at night using CDC light 
traps (CDC Miniature Light Trap, Model 512; John W 
Hock Company) placed indoors in proximity to humans 
sleeping under an untreated net at 18:00 and collected 
at 06:00 the following morning. Trapped Anopheline 
mosquitoes will be identified to species morphologi-
cally and by PCR. Salivary gland sporozoite rates will be 
determined by ELISA on a subset of sampled Anopheles. 
Molecular testing will be done to determine kdr mutation 
frequencies in each cluster (see below for insecticide 
resistance monitoring procedures).
The number of people sleeping in each collection 
room will be recorded and used to estimate the number 
of mosquitoes collected per person-time. This value will be 
multiplied by the observed salivary gland sporozoite rates to 
provide rough estimates of the EIR in different clusters and 
across study arms.31 Additionally, in order to better estimate 
the human biting rates and to estimate indoor:outdoor 
biting ratios, all-night human landing collections will be 
carried out for three consecutive nights per month at four 
houses from each study arm distributed in four clusters.32
The level of vector resistance to various insecticides 
including that on LLINs distributed in 2017 and Actellic 
will be monitored annually. Vector larvae and adults 
will be collected from representative breeding sites and 
households in both IRS and non-IRS areas, and the larvae 
will be reared to adults in the insectary for subsequent 
testing in WHO tube bioassays. In 2017 and 2018, at least 
the following insecticides will be tested using the WHO 
tube test: deltamethrin 0.05%, permethrin (0.75%), 
bendiocarb (0.1%), alpha-cypermethrin (0.05%), pirim-
iphos-methyl (0.25%) and DDT (4%). If resistance is 
detected with the WHO procedure, insecticide resistance 
intensity assays will be conducted based on the standard 
procedures of the CDC bottle assays. As described in the 
intervention section, cone bioassays will be used to eval-
uate quality of spraying and to monitor the decline of 
insecticide efficacy after spraying.
sample sizes and power considerations
Power and sample size calculations conducted using the 
Hayes and Bennett formula33 show that 42 clusters of 
12 children would provide 80% power to detect a 30% 
reduction in the incidence at the community level from 
an estimated baseline of 700/1000 children-year17 at a 
5% significance level. The intercluster correlation used 
is 0.5 given the expected heterogeneity in transmission 
and the presence of displaced populations. To mini-
mise the effect of within-family clustering, efforts will be 
made to avoid enrolling more than only one child per 
household. Number and size of clusters were increased 
to 43 clusters of 12 children to allow for potential loss to 
follow-up.
Each of the cross-sectional surveys will include an 
independent sample of 770 individuals, 385 children 
6–71 months of age and 385 individuals 60 months and 
over. The sample size calculations aim at a 5% precision 
and have been done using estimated populations of 
24 000 children 6–71 months of age and 128 000 children 
Figure 4 Diagram from the Standard Protocol Items: Recommendations for Interventional Trials. LLIN, long-lasting 
insecticide-treated nets; ANC, antenatal clinics.
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60 months and over, and estimated point prevalence of 
54% and 50%, respectively.
Allocation concealment and blinding
The nature of the implementation in villages makes 
blinding to spray status impossible to the teams collecting 
incidence data at the community level. Acknowledging 
this as an inherent limitation, IRS implementation is not 
concealed, yet workers doing the active case detection will 
not be directly informed about the spray status of the clus-
ters they visit.
Analysis will be performed by a statistician blinded to 
the spray status of the clusters.
statistical methods
Primary analysis will be conducted based on intention 
to treat. Analysis of incidence data will be independent 
and based on cluster IRS allocation, regardless of house-
hold refusal/acceptance of spray. To address the primary 
outcome, incidence between spray and no-spray clus-
ters will be compared with a negative binomial regres-
sion model using generalised estimating equations that 
take into account the cluster design effect. Additional 
per-protocol analysis will be adjusted by net usage, net 
integrity and washes, as well as ecological, sociological 
and economic variables in the active cohort.
The cost-effectiveness ratios associated with IRS imple-
mentation will be expressed as cost per (1) episodes or 
(2) deaths averted. Following a societal perspective, the 
incremental cost-effectiveness ratios (ICERs) can be 
expressed as the following:
 
ICER =
[
Costs IRS
(
Actellic
)
−Savings IRS
(
Actellic
)]
−
[
Costs nonIRS−Savings nonIRS
]
Malaria cases or deaths IRS
(
Actellic
)
−Malaria cases or deaths nonIRS
= Costs associated with IRS
(
Actellic
)
−Society savings
Cases or Deaths averted clinical malaria  
The threshold level of the ICERs used to define the imple-
mentation of IRS as cost-effective will be standard levels 
defined by the World Bank and by the WHO.34 35 ICERs will 
also be compared with other malaria interventions in the 
existing literature.36 37
To allow for uncertainty, all model parameters will be 
included as probability distributions rather than as point 
estimates, and probabilistic sensitivity analysis will be subse-
quently undertaken. Kullback-Laibler test for divergence 
between distribution will be used to fit parameter distribu-
tion obtained through data collected in the study. For those 
input parameters where no data are available, ranges will 
be derived from published literature. Monte-Carlo simula-
tions of the probabilistic sensitivity analysis will be used to 
compute ICER SE and the corresponding CI.
DIsCussIon
This study aims at providing Ministries of Health and 
funding partners with additional evidence regarding the 
public health impact and cost-effectiveness of combining the 
most effective vector control tools currently available, LLINs 
and IRS.
Some of the limitations of this study include the lack of 
a clear epidemiological characterisation at baseline and the 
2-year follow-up period that involves practicalities regarding 
sample size and potential loss to follow up (LTFU) (see 
below).
Despite these limitations, this study has many strengths 
that will generate critical information on the cost-effective-
ness and entomological impact of using a next-generation 
IRS product in a context with very high malaria transmis-
sion, existent pyrethroid resistance and high coverage of 
LLINs. These include random allocation of IRS to clearly 
defined clusters with ample buffer zones, which should 
contribute to the reliability of the results. The population 
was closely involved in cluster allocation and has responded 
well during pre-enrolment community mobilisation.
This study also includes rigorous, multiple methods for 
determining intervention impact using both active and 
passive surveillance, entomological data and cross-sectional 
surveys. Sample size calculations took into account poten-
tial LTFU in every cluster and potential loss of up to two full 
clusters. Lastly, this study will prospectively cost both IRS 
implementation and the payer and societal cost of malaria 
in order to determine the cost-effectiveness of the inter-
vention. These data are expected to provide much-needed 
information to guide future vector control decisions in 
Mozambique and in similar settings.
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